Inhibition of α-smooth muscle actin expression and migration of pterygium fibroblasts by coculture with amniotic mesenchymal stem cells.
Sha X., Wen Y., Liu Z., Song L., Peng J., Xie L.
Laboratory Study, published in Curr Eye Res (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Curr Eye Res (2014)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24749888
- DOI
- 10.3109/02713683.2014.900806
Abstract (original English)
Epithelial-mesenchymal transition (EMT) of normal conjunctival tissues is a major reason of pterygium generation; α-smooth muscle actin (α-SMA) is a maker in EMT. In this study, we investigated if human amniotic mesenchymal stem cells (hAMSCs) can inhibit α-SMA expression and migration of human pterygium fibroblasts (hPFs) in vitro. Coculture of hAMSCs and hPFs was completed by using a Transwell coculture system. The α-SMA expression of hPFs was detected by immunocytochemistry and western blot analysis. The migration ability of hPFs was measured by means of a migration assay. Immunoreactivity for α-SMA was detected in all pterygium fibroblasts examined. The expression of α-SMA in cocultured hPFs was significantly lower than in hPFs. Similar result was demonstrated in western blot analysis. In addition, migration assay showed that hAMSCs reduce the migration of hPFs. These results suggested that hAMSCs have the potential to inhibit the generation and invasiveness of pterygium in vitro.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.